Quinine bisulfate
Quinine bisulfate was ranked 456th of 1,796 medicines by items in May 2026, with 12,529 items, down 8.3% on a year earlier.
Dispensed in May 2026
Rolling 12 months
Net ingredient cost · May 2026
Figure 1. Quinine bisulfate: national items dispensed by month
Source: NHSBSA Prescription Cost Analysis, to May 2026
Use this chart on your site
Free to reuse anywhere, including commercially — on your own site, in a report or in an article. Keep the credit link with it and you are done.
A live chart that updates itself when next month's data lands. The credit line is part of the snippet.
An SVG with the title and credit built in. Vector, so it stays sharp at any size in a slide deck or a print layout, and it opens in Illustrator, Figma, Inkscape or any browser.
Paste this beneath the chart if you are using the image rather than the embed.
Chart licensed under CC BY 4.0 — attribution link to PharmaInsight required. Underlying data © NHSBSA, Open Government Licence v3.0.
At a glance
- Therapeutic class Antiprotozoal drugs
- Presentations 1 shown
- Average cost / item £3.37
- Year on year Down 8.3% on a year earlier
Top presentations, May 2026
The individual products dispensed under Quinine bisulfate this month.
| Presentation | BNF code | Items | Net ingredient cost |
|---|---|---|---|
| Quinine bisulfate 300mg tablets | 0504010T0AAAEAE | 12,529 | £42,274 |
Source: NHSBSA Prescription Cost Analysis · to May 2026 OGL v3.0
Where Quinine bisulfate is dispensed
The regions and dispensing practices with the highest Quinine bisulfate volumes.
Top regions
Top dispensing practices
Regional volumes from NHSBSA Prescription Cost Analysis; practice volumes from NHS dispensing data.
Compare Quinine bisulfate with
Other medicines in the same BNF section, by prescribing volume.
Download this data
The monthly series for Quinine bisulfate is in this page's CSV. For the ranked national series across every medicine, with the method and caveats documented, see the most-prescribed medicines dataset in our open data catalogue.